Chapter 3: Pharmacodynamics — Module 2: Dose-Response Relationships, Therapeutic Index and Concentration-Effect Analysis
1. Two bronchodilators are compared in patients with moderate COPD. Drug A reaches maximum bronchodilation (measured as FEV1 improvement) of 35% above baseline at an EC50 of 50 nM. Drug B reaches maximum bronchodilation of 20% above baseline at an EC50 of 5 nM. A pulmonologist switches a patient from Drug B to Drug A despite Drug A's lower potency. Which of the following best justifies this decision?
A) Drug A has a steeper dose-response curve (higher Hill coefficient) than Drug B, allowing more precise dose titration within the therapeutic range despite the lower potency
B) Drug A's higher EC50 means it has a longer duration of action than Drug B -- the higher concentration required means Drug A remains in the therapeutic range for a longer period after each dose
C) Drug B has higher potency and therefore higher clinical utility -- the lower EC50 means Drug B achieves therapeutic bronchodilation at lower plasma concentrations, making it safer and more appropriate for long-term COPD management
D) Drug A has greater efficacy (higher Emax) -- it can produce a maximum bronchodilatory response of 35% above baseline compared to Drug B's ceiling of 20%; in a patient with moderate COPD requiring greater bronchodilation than Drug B can provide regardless of dose, switching to the higher-efficacy Drug A is pharmacodynamically justified even though a higher concentration is required
E) Potency and efficacy are equivalent properties -- Drug A achieves a higher maximum effect precisely because it has a higher EC50, and the two parameters are mathematically linked in the sigmoidal Emax equation
ANSWER: D
Rationale:
This question tests the clinically critical distinction between potency and efficacy. Potency (EC50) determines how much drug is needed to achieve a given level of effect. Efficacy (Emax) determines the maximum effect achievable regardless of dose. Drug B is more potent -- it achieves its maximum effect at a 10-fold lower concentration (EC50 5 nM vs 50 nM). However, Drug B's maximum effect (20% FEV1 improvement) is lower than Drug A's (35%). In a patient whose disease severity requires more than 20% bronchodilation for adequate symptom control, Drug B will fail regardless of how high the dose is pushed -- its Emax is an absolute ceiling. Drug A, despite requiring higher concentrations (lower potency), can achieve the additional bronchodilation the patient needs. This is the fundamental clinical lesson: when maximum effect is the limiting factor rather than dose size, the higher-efficacy drug is preferred even at the cost of potency. This principle applies broadly -- partial agonists (lower Emax) cannot substitute for full agonists in situations where maximum receptor activation is required, regardless of how much lower their EC50 is.
Option A: Option A is incorrect -- the Hill coefficient is not stated to differ between the drugs; steepness of curve is not the basis for this prescribing decision.
Option B: Option B is incorrect -- EC50 does not determine duration of action; duration is governed by the drug's pharmacokinetic half-life and the time course of drug elimination, not by potency.
Option C: Option C is incorrect -- higher potency (lower EC50) does not automatically confer higher clinical utility; when maximum effect is inadequate, potency is irrelevant.
Option E: Option E is incorrect -- potency and efficacy are independent pharmacodynamic properties; EC50 and Emax are mathematically separate parameters in the Hill equation and are not linked; a drug can have any combination of high/low potency and high/low efficacy.
2. A drug with a Hill coefficient of n = 4 is being compared to a drug with n = 1, both with the same EC50 (the concentration producing 50% of maximum effect) and Emax. What is the most important clinical implication of the higher Hill coefficient?
A) A Hill coefficient of 4 produces a steeper sigmoid dose-response curve -- the drug transitions from minimal effect to near-maximum effect over a very narrow concentration range; this has important clinical implications for drugs with narrow therapeutic indices, where small concentration changes above EC50 rapidly produce toxicity and small concentration drops below EC50 produce therapeutic failure; the steep curve reduces the effective therapeutic window even if the nominal TI (TD50/ED50 -- the ratio of the toxic dose to the effective dose in 50% of the population) is unchanged
B) A Hill coefficient of 4 indicates that the drug requires 4-fold higher doses than a drug with n = 1 to achieve the same pharmacological effect at any given concentration within the therapeutic range
C) A Hill coefficient of 4 indicates positive cooperativity in receptor binding, which has no clinical pharmacodynamic consequence because the EC50 and Emax are identical; only affinity and efficacy determine clinical drug behavior
D) A Hill coefficient of 4 means the drug has 4 independent binding sites that must all be occupied simultaneously before any effect occurs -- producing an all-or-none pharmacological response with no graded dose-response relationship
E) A Hill coefficient of 4 results in a shallower dose-response curve than n = 1, providing a wider practical therapeutic window because small dose changes produce proportionally smaller effect changes
ANSWER: A
Rationale:
The Hill coefficient (n) determines the steepness of the sigmoidal concentration-effect curve. When n = 1, the transition from 10% to 90% of maximum effect spans an 81-fold concentration range (from 0.11 × EC50 to 9 × EC50). When n = 4, this same 10-90% transition spans only a 3-fold concentration range. The practical consequence is that a drug with a high Hill coefficient behaves more like a switch than a rheostat -- concentrations slightly below EC50 produce little effect, and concentrations slightly above EC50 produce near-maximum effect. For drugs with narrow therapeutic indices, this steepness dramatically compresses the practical therapeutic window: there is very little concentration range where the drug produces adequate therapeutic effect without approaching toxicity. Even if the nominal TI (TD50/ED50) is the same, the steep curve means that the concentration difference between therapeutic success and toxicity is smaller in practical terms. This is clinically relevant for drugs such as cardiac glycosides, anticonvulsants, and immunosuppressants where the concentration-effect relationship is steep.
Option B: Option B is incorrect -- the Hill coefficient describes the shape of the curve, not a dose multiplier; it does not mean that 4-fold higher doses are required.
Option C: Option C is incorrect -- positive cooperativity reflected by n > 1 has significant clinical pharmacodynamic consequences for the steepness of the response curve and the practical therapeutic window; it is not clinically irrelevant.
Option D: Option D is incorrect -- multiple binding sites producing cooperativity do not require simultaneous full occupancy before any effect; cooperative binding produces graded responses with a steeper curve, not an all-or-none threshold.
Option E: Option E is incorrect -- a higher Hill coefficient produces a steeper, not shallower, curve; the practical therapeutic window is narrowed, not widened.
3. A patient's effective therapeutic index for warfarin is narrower than the population TI = TD50/ED50 would suggest. Which of the following best explains why an individual patient's effective TI can be substantially narrower than the population-derived value?
A) The patient is a CYP2C9 extensive metabolizer, producing more rapid warfarin clearance and requiring higher doses; the higher doses narrow the apparent TI because the toxic threshold is fixed while the effective dose increases
B) The patient takes warfarin inconsistently, producing variable INR values that span both sub-therapeutic and supratherapeutic ranges; the variability itself narrows the effective TI by increasing the probability of spending time in the toxic concentration range
C) The patient has concurrent CYP2C9 inhibition from a new antibiotic, which reduces warfarin clearance and raises plasma warfarin concentrations above the level that was previously therapeutic; the effective ED50 is now achieved at a lower dose while the toxic threshold (TD50) remains at the same plasma concentration -- the gap between therapeutic and toxic exposure is narrowed because any dose that was previously therapeutic now produces supratherapeutic concentrations
D) The population TI for warfarin is already extremely narrow, and all patients regardless of their individual pharmacokinetics have equally narrow effective TIs because the drug's intrinsic pharmacodynamic properties fix the ratio of toxic to effective concentrations
E) The patient's increased vitamin K dietary intake directly raises the EC50 for warfarin's anticoagulant effect by competing with warfarin at the VKORC1 (vitamin K epoxide reductase complex subunit 1) enzyme, requiring higher warfarin doses that bring plasma concentrations closer to the toxic range
ANSWER: C
Rationale:
The population therapeutic index is a statistical construct derived from quantal dose-response curves in large populations -- it reflects the median ratio of toxic to effective doses across diverse individuals. An individual patient's effective TI can be substantially narrower than the population figure for two main reasons: pharmacokinetic changes that raise drug exposure without changing the toxic threshold, or pharmacodynamic changes that increase sensitivity to the drug's effects. CYP2C9 inhibition by a new antibiotic (such as fluconazole, metronidazole, or trimethoprim-sulfamethoxazole) reduces warfarin metabolism. The S-enantiomer of warfarin, which is the more pharmacologically active form and is primarily metabolized by CYP2C9, accumulates when CYP2C9 is inhibited. The plasma warfarin concentration that was previously in the therapeutic range now rises into the supratherapeutic range with the same dose. The concentration at which warfarin produces toxicity (bleeding) has not changed -- but the patient now achieves that concentration at a dose that was previously safe. The effective gap between the therapeutic dose and the toxic dose has narrowed -- the patient's personal TI is now much smaller than the population average. This interaction is one of the most common causes of warfarin-related bleeding events in clinical practice.
Option A: Option A is incorrect -- CYP2C9 extensive metabolizers require higher doses but the TI is not narrowed because both the effective and toxic concentrations scale proportionally; rapid metabolism reduces exposure, requiring dose escalation, but does not compress the therapeutic window.
Option B: Option B is incorrect -- inconsistent dosing produces variability in INR but does not narrow the intrinsic TI; it increases the probability of being outside the therapeutic range but does not change the ratio of toxic to effective concentrations.
Option D: Option D is incorrect -- individual pharmacokinetic and pharmacodynamic variation produces real differences in effective TI between patients; the population TI does not apply uniformly to all individuals.
Option E: Option E is incorrect -- dietary vitamin K does influence warfarin's anticoagulant effect, but it acts by reducing the pharmacodynamic effect (competing at the level of clotting factor synthesis, not at VKORC1 binding), which would increase the dose required but not directly compress the TI in the manner described.
4. A graded dose-response curve is constructed for an opioid analgesic measuring pain scores against drug plasma concentration. The curve reaches a plateau at high concentrations where further dose increases produce no additional analgesia. What pharmacodynamic concept explains this plateau and what determines its height?
A) The ceiling is produced by acute receptor desensitization that occurs simultaneously with receptor activation -- as plasma concentration rises, GRK (G protein-coupled receptor kinase) phosphorylation of mu-opioid receptors reduces their signaling capacity, creating a functional ceiling that is lower than the theoretical Emax
B) The ceiling is a population artifact arising because some patients in the dose-response study reach their maximum tolerated dose before pharmacological Emax is achieved, truncating the apparent plateau below the true pharmacodynamic maximum
C) The ceiling reflects receptor saturation at 100% occupancy, after which all further drug increase is pharmacologically inert -- the height of the plateau is set by the total number of receptors (Bmax) multiplied by the signal produced per receptor
D) The ceiling is determined by the pharmacokinetic half-life of the drug -- once plasma concentrations exceed the drug's elimination capacity, the rate of accumulation plateaus and no further increase in drug effect occurs regardless of dose
E) The ceiling is the Emax -- determined by the drug's intrinsic efficacy at the mu-opioid receptor and the maximum signal transduction capacity of the receptor-effector system; a full mu-opioid agonist such as morphine has a higher Emax for analgesia than a partial agonist such as buprenorphine, which reaches its own lower Emax ceiling that cannot be exceeded regardless of dose or receptor occupancy
ANSWER: E
Rationale:
The plateau of a graded dose-response curve is the Emax -- the maximum pharmacological effect the drug can produce at its receptor system. Emax is an intrinsic property determined by the drug's intrinsic efficacy (its capacity to activate the receptor once bound) and the downstream signal transduction capacity of the receptor-effector system. For mu-opioid agonists, full agonists such as morphine, fentanyl, and oxycodone have high intrinsic efficacy and can produce the maximum analgesic and respiratory depressant response that the opioid system can generate. Partial agonists such as buprenorphine have lower intrinsic efficacy and produce a ceiling effect at a lower Emax -- the analgesic ceiling of buprenorphine is substantially lower than that of full agonists, which limits its utility in severe pain but also means its respiratory depression ceiling is lower (providing a safety advantage in overdose). The Emax is not determined by receptor occupancy alone -- a partial agonist can occupy 100% of receptors and still not achieve the Emax of a full agonist because it activates each receptor less efficiently.
Option A: Option A is incorrect -- while GRK-mediated desensitization does occur with opioid receptor activation, it develops over minutes to hours and is not the primary explanation for the pharmacodynamic plateau in a concentration-effect curve constructed at near-equilibrium conditions.
Option B: Option B is incorrect -- while study design artifacts can truncate observed responses in population studies, the pharmacodynamic plateau is a genuine intrinsic property of the drug-receptor system, not an artifact.
Option C: Option C is incorrect -- 100% receptor occupancy does not automatically produce maximum pharmacological effect; Emax depends on intrinsic efficacy, not just occupancy; a partial agonist at 100% occupancy produces less than Emax of a full agonist.
Option D: Option D is incorrect -- pharmacokinetic half-life determines the time course of drug accumulation and elimination but not the pharmacodynamic ceiling; Emax is a pharmacodynamic property independent of pharmacokinetic parameters.
5. Why does the same dose of phenytoin produce a disproportionately large increase in plasma concentration when a CYP2C9 inhibitor such as fluconazole is added to the regimen?
A) Fluconazole competitively inhibits phenytoin's binding to plasma proteins, increasing the free fraction and producing a disproportionate rise in pharmacologically active unbound phenytoin without changing total plasma concentration
B) At therapeutic plasma concentrations, phenytoin's CYP2C9-mediated hydroxylation is already operating near its maximum velocity (Vmax) -- the elimination pathway is nearly saturated; when fluconazole partially inhibits CYP2C9, the already-limited remaining metabolic capacity is further reduced; because phenytoin is on the near-vertical portion of its Michaelis-Menten elimination curve, even small reductions in Vmax produce disproportionately large increases in steady-state plasma concentration
C) Fluconazole irreversibly destroys CYP2C9 enzyme protein, permanently eliminating phenytoin metabolism until new CYP2C9 is synthesized; the disproportionate rise reflects the complete absence of metabolism rather than partial inhibition
D) Phenytoin transitions from first-order to zero-order kinetics only at toxic plasma concentrations, not at therapeutic levels; fluconazole pushes phenytoin into this toxic kinetic zone by raising concentrations through a separate pharmacokinetic mechanism involving reduced renal tubular secretion of phenytoin metabolites
E) At therapeutic plasma concentrations, phenytoin saturates its own intestinal absorption capacity; fluconazole inhibits intestinal P-glycoprotein, which normally limits phenytoin absorption, producing a disproportionate increase in bioavailability that raises plasma concentrations independently of hepatic metabolism
ANSWER: B
Rationale:
This question integrates the non-linear pharmacokinetics of phenytoin with drug interaction pharmacology. Phenytoin's hepatic CYP2C9-mediated elimination follows Michaelis-Menten kinetics and becomes saturated within the therapeutic concentration range (10-20 mg/L). At therapeutic concentrations, CYP2C9 is operating at 80-90% of its maximum velocity -- it is nearly saturated and can process very little additional phenytoin per unit increase in concentration. The steady-state plasma concentration of phenytoin is determined by the balance between the rate of dosing (input) and the rate of elimination (output). When fluconazole -- a potent CYP2C9 inhibitor -- is added, it further reduces the already-limited residual metabolic capacity. Because elimination is nearly saturated, even a modest reduction in Vmax produces a disproportionately large rise in plasma concentration. This is the essence of Michaelis-Menten kinetics operating near saturation: the system is extremely sensitive to perturbations when Vmax is nearly reached. Clinically, this interaction is well-documented and can precipitate phenytoin toxicity (nystagmus, ataxia, drowsiness, diplopia) at previously well-tolerated doses. Phenytoin levels must be monitored when any CYP2C9 inhibitor is added or removed.
Option A: Option A is incorrect -- fluconazole does not significantly compete with phenytoin for plasma protein binding; protein binding displacement is generally not a clinically meaningful mechanism of drug interaction for phenytoin.
Option C: Option C is incorrect -- fluconazole is a reversible CYP2C9 inhibitor (primarily through coordination of its triazole nitrogen with the heme iron of CYP2C9); it does not irreversibly destroy the enzyme protein.
Option D: Option D is incorrect -- phenytoin operates in non-linear (Michaelis-Menten) kinetics within the therapeutic range, not only at toxic concentrations; fluconazole acts through CYP2C9 inhibition, not through renal tubular secretion.
Option E: Option E is incorrect -- phenytoin absorption is not primarily limited by intestinal P-glycoprotein; fluconazole's clinical interaction with phenytoin is through hepatic CYP2C9 inhibition, not through altered intestinal bioavailability.
ANSWER KEY: Q1=D Q2=A Q3=C Q4=E Q5=B
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.